



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
305158-999193
(Formerly 6750-195-999)

APPLICATION NO.
10/669,875

APPLICANT
CHEN et al.

FILING DATE
09-23-03

GROUP
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	A01	5,039,680	08-13-91	Imperato et al.	514	304	
W	A02	5,075,341	12-24-91	Mendelson et al.	514	282	
W	A03	5,198,459	03-30-93	Imperato et al.	514	397	
W	A04	5,232,934	08-03-93	Downs	514	345	
W	A05	5,556,837	09-17-96	Nestler et al.	514	21	
W	A06	5,556,838	09-17-96	Mayer et al.	514	25	
W	A07	5,574,052	11-12-96	Rose et al.	514	343	
W	A08	5,762,925	06-09-98	Sagen	424	93.7	
W	A09	6,109,269	08-29-00	Rise et al.	128	898	
W	A10	6,204,284	03-20-01	Beer et al.	514	412	
W	A11	5,922,872	07-13-99	Cook et al.	544	368	
W	A12	5,473,072	12-05-95	Mezei et al.	544	295	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
W	A13	EP 0 634 411 A	01-18-95	EPO			XX	
W	A14	JP 06 310786 A	01-18-88	Japan			XX	
W	A15	WO 99/37304	07-29-99	PCT				
W	A16	WO 02/08221 A2	01-31-02	PCT				
W	A17	WO 02/16318 A1	02-28-02	PCT				
W	A18	WO 02/072536 A1	09-19-02	PCT				
W	A19	WO 02/076946 A2	10-03-02	PCT				
W	A20	WO 02/076946 A3	10-03-02	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

VP	A21	Bartho et al., "Involvement of Capsaicin-Sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation," Naunyn-Schmiedeberg's Archives of Pharmacology, 342:666-670 (1990)
	A22	Berkow et al., "The Merck Manual of Medical Information," pp. 345-350, 1997.
	A23	Berkow et al., "The Merck Manual of Medical Information," pp. 352-355, 1997.
	A24	Berkow et al., "The Merck Manual of Medical Information," pp. 496-500, 1997.
	A25	Berkow et al., "The Merck Manual of Medical Information," pp. 525-526, 1997.
	A26	Berkow et al., "The Merck Manual of Medical Information," pp. 528-530, 1997.
	A27	Berkow et al., "The Merck Manual of Medical Information," pp. 530-532, 1997.
	A28	Berkow et al., "The Merck Manual of Medical Information," pp. 631-634, 1997.
	A29	Buchwald et al., "Long-term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis," Surgery 88:507 (1980)
	A30	Chiamulera et al., "Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Mice," Nature Neuroscience 4(9):873-874 (2001)
	A31	Cooke, "Glycopyrrolate in Bladder Dysfunction," SA Medical Journal, 63:3 (1983)
	A32	D'Amour et al., "A Method for Determining Loss of Pain Sensation," J. Pharmacol. Exp. Ther. 72:74-79 (1941)
	A33	Di Marzo et al., "Endovanilloid Signaling in Pain," Current Opinion in Neurobiology 12:372-379 (2002)
	A34	Dogrul et al., Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, a Metabotropic Glutamate Receptor (mGluR ₅) Antagonist, in Experimental Neuropathic Pain in Rats," Neuroscience Letters 292(2):115-118 (2000)
	A35	During et al., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol. 25:351 (1989)
	A36	Foley, "Pain" Cecil Textbook of Medicine, pp. 100-107, (1996)
	A37	Fundytus et al., "Antisense Oligonucleotide Knockdown of mGluR ₁ Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation," Pharmacology, Biochemistry & Behavior 73:401-410 (2002)
	A38	Fundytus et al., "Effect of Activity at Metabotropic, as well as Ionotropic (NMDA), Glutamate Receptors on Morphine Dependence," British Journal of Pharmacology 113:1215-20 (1994)
	A39	Fundytus et al., "In Vivo Antinociceptive Activity of Anti-Rat mGluR ₁ and mGluR ₅ Antibodies in Rats," NeuroReport 9:731-735 (1998)
	A40	Fundytus et al., "Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR ₁) Alleviates Pain and Restores Opioid Efficacy After Nerve Injury in Rats," British Journal of Pharmacology 132:354-367 (2001)
	A41	Fundytus, "Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain," CNS Drugs 15:29-58, (2001)
	A42	Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (L. Brunton, author; J. Hardman and L. Limbird eds., 9 th ed. 1996).
	A43	Hargreaves et al., "A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia," Pain 32(1):77-88 (1988)
	A44	Herzog et al., "Urinary Incontinence: Medical and Psychosocial Aspects," Annu. Rev. Gerontol. Geriatr. 9:74-119, (1989)
	A45	Howard et al., "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," J. Neurosurg. 71:105 (1989)
	A46	Jhamandas et al., "Spinal Amino Acid Release and Precipitated Withdrawal in Rats Chronically Infused with Spinal Morphine," The Journal of Neuroscience 16(8):2758-66 (April 15, 1996)
	A47	Kim, "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat," Pain 50(3):355-363 (1992)
	A48	Komissarov et al., Chemical Abstracts, Columbus, Ohio, US, abstract no. 115:105837z: "Anxiolytic Activity of 1-(2-Pyrimidinyl) Piperazine Deriv.," Khim.-Farm. Zh., vol. 25, no. 3, 1991, pages 40-42, USSR (and English language abstract)
W	A49	Langer, "New Methods of Drug Delivery," Science 249:1527-1533 (1990)

M	A50	Levin et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder," <i>The Journal of Urology</i> , 128:396-398 (1982)
	A51	Levy et al., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> 228:190 (1985)
	A52	Masu et al., "Sequence and Expression of a Metabotropic Glutamate Receptor," <i>Nature</i> , 349:760-765 (1991)
	A53	Miller et al., "Growth Factor Upregulation of a Phosphoinositide-Coupled Metabotropic Glutamate Receptor in Cortical Astrocytes", <i>The Journal of Neuroscience</i> 15(9):6103-6109 (1995)
	A54	Mirakhur et al., "Glycopyrrolate: Pharmacology and Clinical Use," <i>Anaesthesia</i> 38:1195-1204 (1983)
	A55	Ossowska et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-Like Effects in Rats," <i>Neuropharmacology</i> 41:413-420 (2001)
	A56	Langer et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem.</i> 23:61 (1983)
	A57	Resnick, "Urinary Incontinence," <i>Lancet</i> 346:94-99 (1995)
	A58	Saudek et al., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> 321:574 (1989)
	A59	Sefton, "Implantable Pumps," <i>CRC Crit. Ref. Biomed. Eng.</i> 14:201 (1987)
	A60	Seltzer et al., "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury," <i>Pain</i> 43:205-218 (1990)
	A61	Sharif et al., "Attenuation of Morphine Tolerance After Antisense Oligonucleotide Knock-Down of Spinal mGluR1," <i>British Journal of Pharmacology</i> 136:865-72 (2002)
	A62	Spooren et al., "Novel Allosteric Antagonists Shed Light on mglu ₅ Receptors and CNS Disorders," <i>Trends in Pharmacological Sciences</i> , 22(7):331-337 (2001)
	A63	Stein, "Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds," <i>Pharmacology Biochemistry and Behavior</i> 31:451-455 (1988)
	A64	Tatarczynska et al., "Potential Anxiolytic- and Antidepressant-Like Effects of MPEP, a Potent, Selective and Systemically Active mGlu5 Receptor Antagonist," <i>British Journal of Pharmacology</i> 132(7):1423-1430 (2001)
	A65	Treit, "Animal Models for the Study of Anti-Anxiety Agents: A Review," <i>Neuroscience & Biobehavioral Reviews</i> 9(2):203-222 (1985)
	A66	Walker et al., "Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. I. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain," <i>Neuropharmacology</i> 40:1-9 (2001)
M	A67	Wein, "Pharmacology of Incontinence," <i>Urologic Clinics of North America</i> , 22(3):557-577 (1995)

EXAMINER

V. Balasubramanyam

DATE CONSIDERED

9/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT
(Use separate sheets if necessary)

ATTY DOCKET NO.

6750-195-999

(CAM: 305158-999193)

APPLICATION NO.

10/669,875

APPLICANT

Zhengming CHEN et al.

FILING DATE

September 23, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	B01	5,015,642	05-14-91	Lerch et al.			
M	B02	5,025,010	06-18-91	Oekonomopulos et al.			
M	B03	5,081,113	01-14-92	Claussner et al.			
M	B04	5,108,996	04-28-92	Claussner et al.			
M	B05	5,130,315	07-14-92	Ong et al.			
M	B06	5,143,923	09-01-92	Hrib et al.			
M	B07	5,473,072	12-05-95	Mezei et al.			
M	B08	5,478,823	12-26-95	Shibayama et al.			
M	B09	5,486,517	01-23-96	Downing et al.			
M	B10	6,346,622	02-12-02	Lubisch et al.			
M	B11	6,414,157	07-02-02	Lubisch et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
M	B12	JP 63-010760	01-18-88	Japan (w/ English Abstract)			X	
M	B13	GB 2 201 417 A	09-01-88	United Kingdom.				
M	B14	DE 3714371 A1	11-10-88	Germany (w/ English Abstract)			X	
M	B15	WO 98/15546	04-16-98	PCT				
M	B16	WO 00/41697	07-20-00	PCT (w/ English Abstract)			X	
M	B17	Int. Search Report of PCT/US 03/30187	02-16-04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

M	B18	Abramets et al., "Serotonergic and Dopaminergic Mechanisms of the Action of 1-Pyrimidinylpiperazine Derivatives," <i>Eksp. Klin. Farmakol.</i> 55(3):8-11 (1992) (original text in Russian w/ English Abstract)						
M	B19	Dianov et al., "Synthesis and Immunotropic Activity of Thiazole [3,2-A] Benzimidazole Derivatives," <i>Khimiko-Farmatsevticheskii Zhurnal</i> 25(1):40-41 (1991) (original text in Russian w/ English Abstract)						

W	B20	Ishizumi et al., "Synthesis and Anxiolytic Activity of <i>N</i> -Substituted Cyclic Imides (1R*,2S*,3R*,4S*)-N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide (Tandospirone) and Related Compounds," <i>Chem. Pharm. Bull.</i> 39(9):2288-2300 (1991)
M	B21	Kartal et al., "Liquid Chromatographic Method for the Analysis of Buspirone HCl and Its Potential Impurities," <i>Journal of Chromatographic Science</i> 38:151-156 (2000)
W	B22	Naletov et al., "Analysis of Structure-Antiemetic Activity Relations of Piperazinylalkyl Derivatives of Cyclic Imides," <i>Khimiko-Farmatsevticheskii Zhurnal</i> 31(9):35-40 (1997) (original text in Russian w/ English Abstract)
W	B23	Welch et al., "A General Synthetic Method Suitable for the Introduction of Deuterium or Tritium in Buspirone Type Anxiolytic Agents," <i>Journal of Labelled Compound and Radiopharmaceuticals</i> 27(6):701-706 (1988)

EXAMINER <i>V. Balasubraman</i>	DATE CONSIDERED <i>9/2/08</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	